Peptide Comparison
DaptomycinvsThymalin
Cyclic lipodepsipeptide antibiotic containing 13 amino acids and a decanoyl lipid tail from Streptomyces roseosporus — FDA-approved as Cubicin for complicated skin infections (2003) and S. aureus bacteremia including right-sided endocarditis (2006), operating through calcium-dependent phosphatidylglycerol-specific membrane depolarization with rapid bactericidal activity against MRSA, VRE, and other multidrug-resistant Gram-positive pathogens
Russian thymic peptide complex that rejuvenates immune function and supports healthy aging
At a Glance
Quick
comparison
Dose Range
Daptomycin
4–6 mg/kg
Thymalin
5–10 mg
Frequency
Daptomycin
Once daily
Thymalin
Once daily
Administration
Daptomycin
Intravenous infusion over 30 minutes (FDA-approved)
Thymalin
Intramuscular injection
Cycle Length
Daptomycin
4-6 weeks
Thymalin
4-6 weeks
Onset Speed
Daptomycin
Rapid (hours to days)
Thymalin
Moderate (1-2 weeks)
Evidence Level
Daptomycin
Strong human trials (Phase 3 or FDA approved)
Thymalin
Limited human trials
Efficacy
Benefit
ratings
Immune
Immune Restoration
Longevity Support
Disease Prevention
Technical Data
Compound
specifications
Daptomycin
Molecular Formula
C₇₂H₁₀₁N₁₇O₂₆
Molecular Weight
1,620.69 Da
Half-Life
Terminal half-life: 8-9 hours in healthy adults with normal renal function; supports once-daily dosing; post-antibiotic effect: 1-6 hours against S. aureus; renal dose adjustment: CrCl <30 mL/min — extend interval to every 48 hours
Bioavailability
IV: 100% (direct administration); not orally bioavailable (degraded in GI tract); inactivated in lungs by pulmonary surfactant
CAS Number
103060-53-3
Thymalin
Molecular Formula
Complex mixture; active dipeptide EW: C16H19N3O5
Molecular Weight
Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da
Half-Life
Not precisely characterized for complex; immune effects persist weeks post-administration
Bioavailability
High via intramuscular or subcutaneous injection
CAS Number
63958-90-7
Protocols
Dosing
tiers
Daptomycin
Thymalin
Applications
Best
suited for
Daptomycin
Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
Daptomycin is particularly well-suited for individuals focused on treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
Daptomycin is particularly well-suited for individuals focused on complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
Daptomycin is particularly well-suited for individuals focused on vre bloodstream infections and endocarditis when ampicillin-based therapy is not feasible. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Daptomycin is particularly well-suited for individuals focused on outpatient parenteral antibiotic therapy (opat) for gram-positive infections requiring iv treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymalin
Aging Adults Seeking Immune Support
Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.
Longevity and Anti-Aging Protocols
Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.
Seasonal Illness Prevention
Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.
Safety Profile
Side
effects
Daptomycin
Common
- CPK elevation
- GI effects (nausea, diarrhea, vomiting)
- Headache and insomnia
- Injection site reactions
Uncommon
- Eosinophilic pneumonia
Serious
- Rhabdomyolysis
Thymalin
Common
- No side effects in most patients
- Mild injection site reaction
Uncommon
- Transient low-grade fever
- Mild flu-like symptoms
- Temporary headache
Serious
- Severe allergic reaction
Research Status
Safety
& evidence
Daptomycin
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Daptomycin is an FDA-approved antibiotic with extensive clinical safety data from Phase 2/3 trials and post-market pharmacovigilance spanning over 20 years. Key safety concerns include muscle toxicity (creatine phosphokinase elevation) occurring in 3-12% of treated patients, potentially progressing to myopathy with weakness if unmonitored. Pulmonary toxicity (eosinophilic pneumonia) is rare (<1%) but serious. Peripheral neuropathy, nausea, and injection site reactions are common but usually mild. Creatinine elevation in renal impairment is significant—dosing must be reduced in patients with eGFR <30 mL/min. CPK monitoring is essential during treatment, especially in patients on statins or with baseline elevations.
Contraindications
- xKnown hypersensitivity to daptomycin or any component of the formulation
- xPneumonia or any lower respiratory tract infection — daptomycin is inactivated by pulmonary surfactant (phosphatidylcholine) and will fail to treat pneumonia
- xConcurrent use of HMG-CoA reductase inhibitors (statins) is relatively contraindicated — consider temporary discontinuation to reduce risk of additive myotoxicity
- xPre-existing significant skeletal muscle disease or unexplained CPK elevation >5x ULN
Thymalin
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.
Contraindications
- xActive thymic tumors or malignancies
- xKnown hypersensitivity to animal-derived peptide products
- xPregnancy and breastfeeding (insufficient safety data)
- xSevere uncontrolled autoimmune disease without medical supervision
Decision Guide
Which is
right for you?
Choose Daptomycin if...
- Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
- Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
- VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
- Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Choose Thymalin if...
- Immune system restoration in aging adults
- Longevity and healthy aging support
- Reducing infection frequency and severity
- Multi-system health optimization